Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - Phenoxodiol is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called signal transduction inhibitors. (en)
|
http://linked.open...generalReferences
| - # Herst PM, Petersen T, Jerram P, Baty J, Berridge MV: The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells. Biochem Pharmacol. 2007 Dec 3;74(11):1587-95. Epub 2007 Aug 19. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17904534 # Choueiri TK, Wesolowski R, Mekhail TM: Phenoxodiol: isoflavone analog with antineoplastic activity. Curr Oncol Rep. 2006 Mar;8(2):104-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16507219 # Mor G, Fu HH, Alvero AB: Phenoxodiol, a novel approach for the treatment of ovarian cancer. Curr Opin Investig Drugs. 2006 Jun;7(6):542-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16784025 # Klein R, Brown D, Turnley AM: Phenoxodiol protects against Cisplatin induced neurite toxicity in a PC-12 cell model. BMC Neurosci. 2007 Aug 1;8:61. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17672914 (en)
|
http://linked.open...gy/drugbank/group
| |
http://linked.open...ugbank/indication
| - Intended for the treatment of various forms of cancer. (en)
|
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells. Results from one study (PMID: 17904534) indicate that plasma membrane electron transport (PMET) may be a primary target for phenoxodiol in tumour cells and in activated T cells. (en)
|
http://linked.open.../drugbank/synonym
| - 3-(4-Hydroxyphenyl)-2H-1-benzopyran-7-ol (en)
- Dehydroequol (en)
- Haginin E (en)
- Idronoxil (en)
- NV-06 (en)
- NV06 (en)
|
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |
http://linked.open...k/Bioavailability
| |
http://linked.open...bank/Ghose-Filter
| |
http://linked.open...nk/MDDR-Like-Rule
| |
http://linked.open...k/Number-of-Rings
| |
http://linked.open...siological-Charge
| |
http://linked.open...bank/Rule-of-Five
| |
http://linked.open...tional-IUPAC-Name
| |
http://linked.open...strongest-acidic-
| |
http://linked.open...-strongest-basic-
| |